0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML PREFILLED SYRINGE [GARDASIL 9]

Side Effects & Adverse Event Reports


View Chart Data

28

Adverse Events

532

Side Effects

2013

Data Starting In

This report has a limited number of adverse event reports which may not fully reflect the safety profile of this product. It's important to understand that:

  • Only manufacturers are required to report adverse events — for everyone else, reporting is voluntary.
  • It's estimated that only about 10% of adverse events are ever reported.
  • Some people may not realize their experience qualifies as an adverse event.
  • Others may assume someone else has already reported the issue.
  • A lack of awareness about how and where to report can also reduce submissions.
Your report can help close this gap. Whether your experience was mild or serious, sharing it contributes to a fuller understanding of product safety and can help others make better health decisions.

SymPedia Mobile App

Get our Mobile App for easy access to the latest reports on 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML PREFILLED SYRINGE [GARDASIL 9].

Understanding the potential Side Effects and Adverse Events of 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML PREFILLED SYRINGE [GARDASIL 9] is essential for making informed health decisions. Our application provides in-depth reports based on real-world data, helping you explore how 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML PREFILLED SYRINGE [GARDASIL 9] may affect your health.

View reports containing much more information including:

  • Age group - See how different age ranges experience side effects and adverse reactions.
  • Year - Track trends over time to understand changes in reported issues.
  • Biological sex - Compare how reports vary between men and women.
  • Weight - Examine the impact of body weight on side effects and adverse events.
Download Now

Frequently Asked Questions

Some questions about 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML PREFILLED SYRINGE [GARDASIL 9] are asked frequently. We've answered the most frequent of those questions below

  • How many adverse events have been reported for 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML PREFILLED SYRINGE [GARDASIL 9]?

    SymPedia shows 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML PREFILLED SYRINGE [GARDASIL 9] adverse event reports for 28.

  • How many side effects have been reported for 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML PREFILLED SYRINGE [GARDASIL 9]?

    SymPedia shows 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML PREFILLED SYRINGE [GARDASIL 9] side effect reports for 532.

  • What year does the 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML PREFILLED SYRINGE [GARDASIL 9] reporting data start?

    SymPedia reporting data on this page starts in 2013.

  • What years are included in the yearly chart for 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML PREFILLED SYRINGE [GARDASIL 9]?

    SymPedia yearly chart data on this page covers 2013 to 2025.

  • Is adverse event reporting mandatory?

    SymPedia notes that only manufacturers are required to report adverse events. For other reporters, submission is generally voluntary, which can lead to underreporting.

0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML INJECTION

Side Effects & Adverse Event Reports


View Chart Data

28

Adverse Events

532

Side Effects

2013

Data Starting In

This report has a limited number of adverse event reports which may not fully reflect the safety profile of this product. It's important to understand that:

  • Only manufacturers are required to report adverse events — for everyone else, reporting is voluntary.
  • It's estimated that only about 10% of adverse events are ever reported.
  • Some people may not realize their experience qualifies as an adverse event.
  • Others may assume someone else has already reported the issue.
  • A lack of awareness about how and where to report can also reduce submissions.
Your report can help close this gap. Whether your experience was mild or serious, sharing it contributes to a fuller understanding of product safety and can help others make better health decisions.

SymPedia Mobile App

Get our Mobile App for easy access to the latest reports on 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML INJECTION.

Understanding the potential Side Effects and Adverse Events of 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML INJECTION is essential for making informed health decisions. Our application provides in-depth reports based on real-world data, helping you explore how 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML INJECTION may affect your health.

View reports containing much more information including:

  • Age group - See how different age ranges experience side effects and adverse reactions.
  • Year - Track trends over time to understand changes in reported issues.
  • Biological sex - Compare how reports vary between men and women.
  • Weight - Examine the impact of body weight on side effects and adverse events.
Download Now

Frequently Asked Questions

Some questions about 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML INJECTION are asked frequently. We've answered the most frequent of those questions below

  • How many adverse events have been reported for 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML INJECTION?

    SymPedia shows 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML INJECTION adverse event reports for 28.

  • How many side effects have been reported for 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML INJECTION?

    SymPedia shows 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML INJECTION side effect reports for 532.

  • What year does the 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML INJECTION reporting data start?

    SymPedia reporting data on this page starts in 2013.

  • What years are included in the yearly chart for 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML INJECTION?

    SymPedia yearly chart data on this page covers 2013 to 2025.

  • Is adverse event reporting mandatory?

    SymPedia notes that only manufacturers are required to report adverse events. For other reporters, submission is generally voluntary, which can lead to underreporting.

0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML INJECTION [GARDASIL 9]

Side Effects & Adverse Event Reports


View Chart Data

28

Adverse Events

532

Side Effects

2013

Data Starting In

This report has a limited number of adverse event reports which may not fully reflect the safety profile of this product. It's important to understand that:

  • Only manufacturers are required to report adverse events — for everyone else, reporting is voluntary.
  • It's estimated that only about 10% of adverse events are ever reported.
  • Some people may not realize their experience qualifies as an adverse event.
  • Others may assume someone else has already reported the issue.
  • A lack of awareness about how and where to report can also reduce submissions.
Your report can help close this gap. Whether your experience was mild or serious, sharing it contributes to a fuller understanding of product safety and can help others make better health decisions.

SymPedia Mobile App

Get our Mobile App for easy access to the latest reports on 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML INJECTION [GARDASIL 9].

Understanding the potential Side Effects and Adverse Events of 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML INJECTION [GARDASIL 9] is essential for making informed health decisions. Our application provides in-depth reports based on real-world data, helping you explore how 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML INJECTION [GARDASIL 9] may affect your health.

View reports containing much more information including:

  • Age group - See how different age ranges experience side effects and adverse reactions.
  • Year - Track trends over time to understand changes in reported issues.
  • Biological sex - Compare how reports vary between men and women.
  • Weight - Examine the impact of body weight on side effects and adverse events.
Download Now

Frequently Asked Questions

Some questions about 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML INJECTION [GARDASIL 9] are asked frequently. We've answered the most frequent of those questions below

  • How many adverse events have been reported for 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML INJECTION [GARDASIL 9]?

    SymPedia shows 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML INJECTION [GARDASIL 9] adverse event reports for 28.

  • How many side effects have been reported for 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML INJECTION [GARDASIL 9]?

    SymPedia shows 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML INJECTION [GARDASIL 9] side effect reports for 532.

  • What year does the 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML INJECTION [GARDASIL 9] reporting data start?

    SymPedia reporting data on this page starts in 2013.

  • What years are included in the yearly chart for 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML INJECTION [GARDASIL 9]?

    SymPedia yearly chart data on this page covers 2013 to 2025.

  • Is adverse event reporting mandatory?

    SymPedia notes that only manufacturers are required to report adverse events. For other reporters, submission is generally voluntary, which can lead to underreporting.

0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML PREFILLED SYRINGE

Side Effects & Adverse Event Reports


View Chart Data

28

Adverse Events

532

Side Effects

2013

Data Starting In

This report has a limited number of adverse event reports which may not fully reflect the safety profile of this product. It's important to understand that:

  • Only manufacturers are required to report adverse events — for everyone else, reporting is voluntary.
  • It's estimated that only about 10% of adverse events are ever reported.
  • Some people may not realize their experience qualifies as an adverse event.
  • Others may assume someone else has already reported the issue.
  • A lack of awareness about how and where to report can also reduce submissions.
Your report can help close this gap. Whether your experience was mild or serious, sharing it contributes to a fuller understanding of product safety and can help others make better health decisions.

SymPedia Mobile App

Get our Mobile App for easy access to the latest reports on 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML PREFILLED SYRINGE.

Understanding the potential Side Effects and Adverse Events of 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML PREFILLED SYRINGE is essential for making informed health decisions. Our application provides in-depth reports based on real-world data, helping you explore how 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML PREFILLED SYRINGE may affect your health.

View reports containing much more information including:

  • Age group - See how different age ranges experience side effects and adverse reactions.
  • Year - Track trends over time to understand changes in reported issues.
  • Biological sex - Compare how reports vary between men and women.
  • Weight - Examine the impact of body weight on side effects and adverse events.
Download Now

Frequently Asked Questions

Some questions about 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML PREFILLED SYRINGE are asked frequently. We've answered the most frequent of those questions below

  • How many adverse events have been reported for 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML PREFILLED SYRINGE?

    SymPedia shows 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML PREFILLED SYRINGE adverse event reports for 28.

  • How many side effects have been reported for 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML PREFILLED SYRINGE?

    SymPedia shows 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML PREFILLED SYRINGE side effect reports for 532.

  • What year does the 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML PREFILLED SYRINGE reporting data start?

    SymPedia reporting data on this page starts in 2013.

  • What years are included in the yearly chart for 0.5 ML L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE 0.12 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE 0.08 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 31 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 VACCINE 0.04 MG/ML / L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 VACCINE 0.06 MG/ML PREFILLED SYRINGE?

    SymPedia yearly chart data on this page covers 2013 to 2025.

  • Is adverse event reporting mandatory?

    SymPedia notes that only manufacturers are required to report adverse events. For other reporters, submission is generally voluntary, which can lead to underreporting.